Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

Home
/
update
/
details

REVEAL GENOMICS and IEO Launch Impact Study on HER2DX® Test to Advance Personalized Treatment in HER2+ Breast Cancer

NextEdge Admin

05 Dec 2024

2 min 17 sec

biotechnology,HER2+ breast cancer,diagnostics,personalized care

REVEAL GENOMICS, S.L., a biotechnology start-up from Barcelona, and the Istituto Europeo di Oncologia (IEO) have launched a groundbreaking impact study on the HER2DX® test, the first genomic test globally dedicated to HER2+ breast cancer.

The study, titled "HER2-BREAST-DX: Prospective Observational Monocentric Study to Evaluate the Impact of the HER2DX® Assay on Treatment Decisions in Early-Stage HER2+ Breast Cancer," focuses on patients with localized HER2+ breast cancer (stage I-IIIA). It aims to assess how HER2DX® influences treatment strategies, particularly in deciding between neoadjuvant (pre-surgery) or adjuvant (post-surgery) therapies. By tailoring therapeutic approaches, the project strives to advance personalized oncology care.

The initiative is a collaboration between REVEAL GENOMICS®, IEO, and the Umberto Veronesi Foundation, which funds the study and supports excellence in scientific research, prevention, and health education. This partnership underscores IEO's dedication to integrating HER2DX® into clinical practice and measuring its effect on oncologists’ decision-making processes.

Dr. Patricia Villagrasa-González, CEO and co-founder of REVEAL GENOMICS®, highlights that the study complements ongoing research in Spain, reinforcing HER2DX® as a robust tool for clinical use. She emphasizes the benefits of collaborating with esteemed institutions like IEO to promote the test’s adoption across Europe.

Dr. Carmen Criscitiello, medical oncologist at IEO and principal investigator, expresses enthusiasm for the study's potential to refine treatments for HER2+ breast cancer patients, aligning with IEO’s mission to enhance patient outcomes through personalized care.